These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 37331331

  • 1. Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa.
    Argyropoulou M, Trigoni A, Kaffenberger J, Stergianou D, Damoraki G, Mingiani E, Micha S, Krispinsky A, Meltzanidou P, Kanni T, Lazaridou E, Giamarellos-Bourboulis EJ.
    Dermatology; 2023; 239(5):746-752. PubMed ID: 37331331
    [Abstract] [Full Text] [Related]

  • 2. Staphylococcus aureus Carriage in Hidradenitis Suppurativa: Impact on Response to Adalimumab.
    Stergianou D, Tzanetakou V, Argyropoulou M, Kanni T, Bagos PG, Giamarellos-Bourboulis EJ.
    Dermatology; 2021; 237(3):372-377. PubMed ID: 33401280
    [Abstract] [Full Text] [Related]

  • 3. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
    Caposiena Caro RD, Cannizzaro MV, Tartaglia C, Bianchi L.
    Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
    [Abstract] [Full Text] [Related]

  • 4. Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa.
    Savva A, Kanni T, Damoraki G, Kotsaki A, Giatrakou S, Grech I, Katoulis A, Papadavid E, Giamarellos-Bourboulis EJ.
    Br J Dermatol; 2013 Feb; 168(2):311-7. PubMed ID: 23106544
    [Abstract] [Full Text] [Related]

  • 5. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.
    Tzellos T, van Straalen KR, Kyrgidis A, Alavi A, Goldfarb N, Gulliver W, Jemec GBE, Lowes MA, Marzano AV, Prens EP, Sayed CJ, van der Zee HH, Zouboulis CC.
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):395-401. PubMed ID: 36184889
    [Abstract] [Full Text] [Related]

  • 6. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
    Frew JW, Jiang CS, Singh N, Grand D, Navrazhina K, Vaughan R, Krueger JG.
    J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
    [Abstract] [Full Text] [Related]

  • 7. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, Teixeira HD, Jemec GB.
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
    [Abstract] [Full Text] [Related]

  • 8. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial.
    Alavi A, Prens EP, Kimball AB, Frew JW, Krueger JG, Mukhopadhyay S, Gao H, Ranganathan U, Ivanoff NB, Hernandez Daly AC, Zouboulis CC.
    Br J Dermatol; 2024 Sep 18; 191(4):508-518. PubMed ID: 38576350
    [Abstract] [Full Text] [Related]

  • 9. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
    Esme P, Akoglu G, Dalkıran CD, Caliskan E.
    Dermatol Ther; 2022 Nov 18; 35(11):e15782. PubMed ID: 35996992
    [Abstract] [Full Text] [Related]

  • 10. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study.
    Hafner A, Ghislain PD, Kovács R, Batchelor R, Katoulis AC, Kirby B, Banayan H, Schonbrun M.
    J Eur Acad Dermatol Venereol; 2021 Nov 18; 35(11):2277-2284. PubMed ID: 34320249
    [Abstract] [Full Text] [Related]

  • 11. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.
    Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, Papp KA, Desjardins O, Jean C.
    J Eur Acad Dermatol Venereol; 2021 Dec 18; 35(12):2431-2439. PubMed ID: 34378812
    [Abstract] [Full Text] [Related]

  • 12. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A, Menter A, Armstrong A, Ocampo C, Gu Y, Teixeira HD.
    J Drugs Dermatol; 2016 Oct 01; 15(10):1192-1196. PubMed ID: 27741335
    [Abstract] [Full Text] [Related]

  • 13. A Genetic Variant in the BCL2 Gene Associates with Adalimumab Response in Hidradenitis Suppurativa Clinical Trials and Regulates Expression of BCL2.
    Liu M, Degner J, Georgantas RW, Nader A, Mostafa NM, Teixeira HD, Williams DA, Kirsner RS, Nichols AJ, Davis JW, Waring JF.
    J Invest Dermatol; 2020 Mar 01; 140(3):574-582.e2. PubMed ID: 31465739
    [Abstract] [Full Text] [Related]

  • 14. Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results.
    Morita A, Takahashi H, Ozawa K, Imafuku S, Takekuni N, Takahashi K, Matsuyama T, Okubo Y, Zhao Y, Kitamura S, Takei K, Yokoyama M, Hayashi N, Terui T.
    J Dermatol; 2021 Jan 01; 48(1):3-13. PubMed ID: 33029861
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
    Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, Rolleri R, Seegobin S, Baeten D, Ionescu L, Zouboulis CC, Shaw S.
    JAMA Dermatol; 2021 Nov 01; 157(11):1279-1288. PubMed ID: 34406364
    [Abstract] [Full Text] [Related]

  • 16. Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.
    Dudink K, Bouwman K, Chen Y, DePrimo SE, Munoz-Elias EJ, Aarts P, Schappin R, Florencia EF, van Heeswijk B, Prens LM, van der Zee HH, Prens EP, van Straalen KR, Horváth B.
    Br J Dermatol; 2023 Apr 20; 188(5):601-609. PubMed ID: 36811949
    [Abstract] [Full Text] [Related]

  • 17. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
    Jemec GBE, Okun MM, Forman SB, Gulliver WPF, Prens EP, Mrowietz U, Armstrong AW, Geng Z, Gu Y, Williams DA, Teixeira HD, Kimball AB.
    Br J Dermatol; 2019 Nov 20; 181(5):967-975. PubMed ID: 30916379
    [Abstract] [Full Text] [Related]

  • 18. Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies.
    Giamarellos-Bourboulis EJ, Sobell J, Ryan C, Wolkenstein PJ, Geng Z, Mulder GD.
    Wounds; 2017 Nov 20; 29(11):E98-E102. PubMed ID: 29166256
    [Abstract] [Full Text] [Related]

  • 19. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab.
    Frew JW, Jiang CS, Singh N, Grand D, Navrazhina K, Vaughan R, Krueger JG.
    Clin Exp Dermatol; 2021 Mar 20; 46(2):306-313. PubMed ID: 32931599
    [Abstract] [Full Text] [Related]

  • 20. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I, Brkić J, Ćorluka M, Čović M, Pejić J, Zeljko Penavić J.
    Acta Dermatovenerol Croat; 2021 Jul 20; 29(2):108-110. PubMed ID: 34477078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.